KMDA
Price
$6.71
Change
+$0.01 (+0.15%)
Updated
Apr 2 closing price
Capitalization
306.49M
54 days until earnings call
RDY
Price
$13.23
Change
+$0.07 (+0.53%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
12.48B
37 days until earnings call
Ad is loading...

KMDA vs RDY

Header iconKMDA vs RDY Comparison
Open Charts KMDA vs RDYBanner chart's image
Kamada
Price$6.71
Change+$0.01 (+0.15%)
Volume$48.38K
Capitalization306.49M
Dr. Reddy's Laboratories
Price$13.23
Change+$0.07 (+0.53%)
Volume$16.84K
Capitalization12.48B
KMDA vs RDY Comparison Chart
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. RDY commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and RDY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (KMDA: $6.70 vs. RDY: $13.16)
Brand notoriety: KMDA and RDY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: KMDA: 38% vs. RDY: 99%
Market capitalization -- KMDA: $306.49M vs. RDY: $12.48B
KMDA [@Pharmaceuticals: Other] is valued at $306.49M. RDY’s [@Pharmaceuticals: Other] market capitalization is $12.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 1 green, 4 red.
According to our system of comparison, RDY is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 2 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).

  • KMDA’s TA Score: 2 bullish, 6 bearish.
  • RDY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RDY is a better buy in the short-term than KMDA.

Price Growth

KMDA (@Pharmaceuticals: Other) experienced а -5.37% price change this week, while RDY (@Pharmaceuticals: Other) price change was -2.16% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.45%. For the same industry, the average monthly price growth was -0.08%, and the average quarterly price growth was -9.41%.

Reported Earning Dates

KMDA is expected to report earnings on May 27, 2025.

RDY is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.5B) has a higher market cap than KMDA($306M). KMDA has higher P/E ratio than RDY: KMDA (37.43) vs RDY (19.68). KMDA YTD gains are higher at: 13.338 vs. RDY (-16.656). RDY has higher annual earnings (EBITDA): 84.9B vs. KMDA (22.4M). RDY has more cash in the bank: 72.4B vs. KMDA (55.6M). KMDA has less debt than RDY: KMDA (8.82M) vs RDY (19.9B). RDY has higher revenues than KMDA: RDY (271B) vs KMDA (143M).
KMDARDYKMDA / RDY
Capitalization306M12.5B2%
EBITDA22.4M84.9B0%
Gain YTD13.338-16.656-80%
P/E Ratio37.4319.68190%
Revenue143M271B0%
Total Cash55.6M72.4B0%
Total Debt8.82M19.9B0%
FUNDAMENTALS RATINGS
KMDA vs RDY: Fundamental Ratings
KMDA
RDY
OUTLOOK RATING
1..100
7915
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
8227
SMR RATING
1..100
8148
PRICE GROWTH RATING
1..100
4360
P/E GROWTH RATING
1..100
8260
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (73) in the Biotechnology industry is in the same range as RDY (79) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (27) in the Pharmaceuticals Generic industry is somewhat better than the same rating for KMDA (82) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than KMDA’s over the last 12 months.

RDY's SMR Rating (48) in the Pharmaceuticals Generic industry is somewhat better than the same rating for KMDA (81) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than KMDA’s over the last 12 months.

KMDA's Price Growth Rating (43) in the Biotechnology industry is in the same range as RDY (60) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

RDY's P/E Growth Rating (60) in the Pharmaceuticals Generic industry is in the same range as KMDA (82) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDARDY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
48%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
51%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 10 days ago
69%
Bullish Trend 13 days ago
51%
Declines
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 2 days ago
49%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
42%
Aroon
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
49%
View a ticker or compare two or three
Ad is loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WICVX9.190.14
+1.55%
Wasatch Small Cap Value Institutional
HEQFX4.59N/A
N/A
Monteagle Opportunity Equity Inv
JENRX57.17N/A
N/A
Jensen Quality Growth R
JEEBX15.99N/A
N/A
JHancock Infrastructure A
CREYX10.05N/A
N/A
Columbia Real Estate Equity Inst3

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and INCR have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and INCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+0.15%
INCR - KMDA
27%
Poorly correlated
+0.36%
NXSCF - KMDA
27%
Poorly correlated
N/A
SGIOY - KMDA
27%
Poorly correlated
-1.06%
RDY - KMDA
23%
Poorly correlated
+0.53%
OGI - KMDA
23%
Poorly correlated
-0.96%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and TAK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
-0.23%
TAK - RDY
25%
Poorly correlated
+0.20%
SNDL - RDY
24%
Poorly correlated
+2.13%
KMDA - RDY
24%
Poorly correlated
+1.36%
TEVA - RDY
23%
Poorly correlated
-0.52%
ACET - RDY
23%
Poorly correlated
-2.65%
More